Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2002 Feb;11(1):7–12. doi: 10.1080/09629350210304

The presence of elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation.

U Westin 1, M Nyström 1, I Ljungcrantz 1, B Eriksson 1, K Ohlsson 1
PMCID: PMC1781642  PMID: 11926597

Abstract

Biopsy samples of head and neck carcinomas were investigated with regard to elafin, secretory leukocyte protease inhibitor (SLPI), interleukin 1-receptor antagonist [(IL)1-RA] and soluble tumour necrosis factor alpha receptor antagonist (STNFalpha RI). SLPI and elafin are serine protease inhibitors produced in the serous cells of the upper respiratory airways and in the keratinocytes, respectively. We have now found the presence of elafin and SLPI in squamous cell carcinomas of the upper respiratory tract (tonsillar, hypopharyngeal, tongue, mouth floor, gingival and laryngeal cancer). Significantly higher amounts of SLPI and elafin are present in well-differentiated and moderately differentiated tumours than in poorly differentiated tumours (p < 0.0001 and p < 0.0015). Tumour necrosis factor-alpha and IL-1beta have been shown to stimulate the production of SLPI and elafin. Since these cytokines can both be difficult to detect, we chose to study their inhibitors, STNFalpha RI and IL1-RA, instead. IL1-RA was expressed in highly differentiated tumours as well as in poorly differentiated ones. No significant difference was seen between the groups. STNFalpha RI was only found in very small amounts, sparsely distributed in the tumours, and was not related to the degree of differentiation.

Full Text

The Full Text of this article is available as a PDF (679.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alkemade J. A., Molhuizen H. O., Ponec M., Kempenaar J. A., Zeeuwen P. L., de Jongh G. J., van Vlijmen-Willems I. M., van Erp P. E., van de Kerkhof P. C., Schalkwijk J. SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J Cell Sci. 1994 Aug;107(Pt 8):2335–2342. doi: 10.1242/jcs.107.8.2335. [DOI] [PubMed] [Google Scholar]
  2. Amiguet J. A., Jiménez J., Monreal J. I., Hernández M. J., López-Vivanco G., Vidán J. R., Conchillo F., Liso P. Serum proteolytic activities and antiproteases in human colorectal carcinoma. J Physiol Biochem. 1998 Mar;54(1):9–13. [PubMed] [Google Scholar]
  3. Axelsson L., Linder C., Ohlsson K., Rosengren M. The effect of the secretory leukocyte protease inhibitor on leukocyte proteases released during phagocytosis. Biol Chem Hoppe Seyler. 1988 May;369 (Suppl):89–93. [PubMed] [Google Scholar]
  4. Fryksmark U., Ohlsson K., Polling A., Tegner H. Distribution of antileukoprotease in upper respiratory mucosa. Ann Otol Rhinol Laryngol. 1982 May-Jun;91(3 Pt 1):268–271. doi: 10.1177/000348948209100308. [DOI] [PubMed] [Google Scholar]
  5. Fryksmark U., Ohlsson K., Rosengren M., Tegner H. Studies on the interaction between leukocyte elastase, antileukoproteinase and the plasma proteinase inhibitors alpha 1-proteinase inhibitor and alpha 2-macroglobulin. Hoppe Seylers Z Physiol Chem. 1983 Jul;364(7):793–800. doi: 10.1515/bchm2.1983.364.2.793. [DOI] [PubMed] [Google Scholar]
  6. Gauthier F., Fryksmark U., Ohlsson K., Bieth J. G. Kinetics of the inhibition of leukocyte elastase by the bronchial inhibitor. Biochim Biophys Acta. 1982 Jan 18;700(2):178–183. doi: 10.1016/0167-4838(82)90095-4. [DOI] [PubMed] [Google Scholar]
  7. Janoff A. Elastase in tissue injury. Annu Rev Med. 1985;36:207–216. doi: 10.1146/annurev.me.36.020185.001231. [DOI] [PubMed] [Google Scholar]
  8. Liotta L. A., Steeg P. S., Stetler-Stevenson W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991 Jan 25;64(2):327–336. doi: 10.1016/0092-8674(91)90642-c. [DOI] [PubMed] [Google Scholar]
  9. Liotta L. A. Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 1986 Jan;46(1):1–7. [PubMed] [Google Scholar]
  10. Molhuizen H. O., Alkemade H. A., Zeeuwen P. L., de Jongh G. J., Wieringa B., Schalkwijk J. SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem. 1993 Jun 5;268(16):12028–12032. [PubMed] [Google Scholar]
  11. Ohlsson K., Tegner H. Inhibition of elastase from granulocytes by the low molecular weight bronchial protease inhibitor. Scand J Clin Lab Invest. 1976 Sep;36(5):437–445. doi: 10.3109/00365517609054461. [DOI] [PubMed] [Google Scholar]
  12. Pfundt R., Wingens M., Bergers M., Zweers M., Frenken M., Schalkwijk J. TNF-alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. Arch Dermatol Res. 2000 Apr;292(4):180–187. doi: 10.1007/s004030050475. [DOI] [PubMed] [Google Scholar]
  13. Pfundt R., van Ruissen F., van Vlijmen-Willems I. M., Alkemade H. A., Zeeuwen P. L., Jap P. H., Dijkman H., Fransen J., Croes H., van Erp P. E. Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia. J Clin Invest. 1996 Sep 15;98(6):1389–1399. doi: 10.1172/JCI118926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sallenave J. M., Shulmann J., Crossley J., Jordana M., Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol. 1994 Dec;11(6):733–741. doi: 10.1165/ajrcmb.11.6.7946401. [DOI] [PubMed] [Google Scholar]
  15. Schalkwijk J., Chang A., Janssen P., De Jongh G. J., Mier P. D. Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis. Br J Dermatol. 1990 May;122(5):631–641. doi: 10.1111/j.1365-2133.1990.tb07285.x. [DOI] [PubMed] [Google Scholar]
  16. Thompson R. C., Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6692–6696. doi: 10.1073/pnas.83.18.6692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Travis J., Salvesen G. S. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983;52:655–709. doi: 10.1146/annurev.bi.52.070183.003255. [DOI] [PubMed] [Google Scholar]
  18. Westin U., Fryksmark U., Polling A., Ohlsson K. Localisation of secretory leucocyte proteinase inhibitor mRNA in nasal mucosa. Acta Otolaryngol. 1994 Mar;114(2):199–202. doi: 10.3109/00016489409126042. [DOI] [PubMed] [Google Scholar]
  19. Wiedow O., Lüademann J., Utecht B. Elafin is a potent inhibitor of proteinase 3. Biochem Biophys Res Commun. 1991 Jan 15;174(1):6–10. doi: 10.1016/0006-291x(91)90476-n. [DOI] [PubMed] [Google Scholar]
  20. Wingens M., van Bergen B. H., Hiemstra P. S., Meis J. F., van Vlijmen-Willems I. M., Zeeuwen P. L., Mulder J., Kramps H. A., van Ruissen F., Schalkwijk J. Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes. J Invest Dermatol. 1998 Dec;111(6):996–1002. doi: 10.1046/j.1523-1747.1998.00425.x. [DOI] [PubMed] [Google Scholar]
  21. Zhang M., Zou Z., Maass N., Sager R. Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level. Cancer Res. 1995 Jun 15;55(12):2537–2541. [PubMed] [Google Scholar]
  22. van Wetering S., van der Linden A. C., van Sterkenburg M. A., Rabe K. F., Schalkwijk J., Hiemstra P. S. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. J Investig Med. 2000 Sep;48(5):359–366. [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES